Featured Publications
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients
Forrest JK, Deeb GM, Yakubov SJ, Rovin JD, Mumtaz M, Gada H, O'Hair D, Bajwa T, Sorajja P, Heiser JC, Merhi W, Mangi A, Spriggs DJ, Kleiman NS, Chetcuti SJ, Teirstein PS, Zorn GL, Tadros P, Tchétché D, Resar JR, Walton A, Gleason TG, Ramlawi B, Iskander A, Caputo R, Oh JK, Huang J, Reardon MJ. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. Journal Of The American College Of Cardiology 2022, 79: 882-896. PMID: 35241222, DOI: 10.1016/j.jacc.2021.11.062.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut Low Risk trialLow-risk trialsAortic valve replacementPrimary endpointRisk trialsCause mortalityValve replacementTranscatheter Versus Surgical Aortic Valve ReplacementLow surgical risk patientsSurgical aortic valve replacementIndependent clinical events committeeEchocardiographic core laboratoryKaplan-Meier ratesSevere aortic stenosisClinical events committeeLow-risk patientsCause mortality ratesSelf-expanding valvesDisabling strokeEchocardiographic outcomesSurgical AVRTAVR groupSurgery groupAdverse eventsTranscatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry
Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, Jilaihawi H, Liu F, Reardon MJ. Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2020, 13: 1749-1759. PMID: 32473890, DOI: 10.1016/j.jcin.2020.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisBicuspid Aortic Valve DiseaseFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProsthesis DesignRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsAortic valve stenosisBicuspid aortic valve stenosisTranscatheter aortic valve replacementEvolut PRO valveAortic valve replacementValve stenosisTVT RegistryCause mortalityValve replacementEvolut RBicuspid valveBicuspid Versus Tricuspid Aortic ValvesSTS/ACC TVT RegistryThoracic Surgeons/American CollegeTricuspid aortic valve stenosisCardiology TVT (Transcatheter Valve Therapy) RegistryTricuspid aortic stenosisRate of strokeSelf-expanding valvesLow complication rateTricuspid aortic valveAcceptable safety outcomesCardiac comorbiditiesEchocardiographic outcomesAortic stenosisEarly Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovascular Interventions 2018, 11: 160-168. PMID: 29348010, DOI: 10.1016/j.jcin.2017.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisCause of DeathEchocardiographyFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMitral Valve InsufficiencyPericardiumProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsSelf-expanding transcatheter aortic valveSevere symptomatic aortic stenosisEvolut PRO valveSymptomatic aortic stenosisTranscatheter aortic valveAortic stenosisParavalvular leakAortic valveValve Academic Research Consortium-2 criteriaIndependent echocardiographic core laboratoryTranscatheter aortic valve replacementTranscatheter aortic valve systemEchocardiographic core laboratoryPrimary safety endpointPrimary efficacy endpointRemainder of patientsAortic valve replacementProportion of patientsProsthetic valve regurgitationSupra-annular valveEffective orifice areaDisabling strokeCause mortalityEfficacy endpointSafety endpoint
2024
3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study
Zahr F, Ramlawi B, Reardon M, Deeb G, Yakubov S, Song H, Kleiman N, Chetcuti S, Gada H, Mumtaz M, Leung S, Merhi W, Rovin J, DeFrain M, Muppala M, Kauten J, Rajagopal V, Huang J, Ito S, Forrest J. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC Cardiovascular Interventions 2024, 17: 1667-1675. PMID: 39048253, DOI: 10.1016/j.jcin.2024.05.017.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBicuspid Aortic Valve DiseaseBioprosthesisFemaleHeart Valve DiseasesHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProspective StudiesProsthesis DesignRecovery of FunctionRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementRates of all-cause mortalityAll-cause mortalityAortic stenosisThoracic Surgeons Predicted Risk of Mortality scoreThoracic Surgeons Predicted RiskSevere paravalvular aortic regurgitationBicuspid aortic valve anatomyRisk of Mortality scoreEchocardiographic core laboratoryLow-surgical risk patientsAortic valve anatomyKaplan-Meier ratesLow surgical riskClinical events committeeAortic valve replacementSevere aortic stenosisParavalvular aortic regurgitationPermanent pacemaker implantationBicuspid aortic stenosisFavorable hemodynamic performanceEvaluated 3 yearsAttempted implantEchocardiographic outcomesAortic regurgitationReinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis
Grubb K, Lisko J, O'Hair D, Merhi W, Forrest J, Mahoney P, Van Mieghem N, Windecker S, Yakubov S, Williams M, Chetcuti S, Deeb G, Kleiman N, Althouse A, Reardon M. Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis. JACC Cardiovascular Interventions 2024, 17: 1007-1016. PMID: 38573257, DOI: 10.1016/j.jcin.2024.01.292.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIncidenceMalePostoperative ComplicationsProsthesis DesignRandomized Controlled Trials as TopicRetreatmentRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementIncidence of reinterventionAortic valve replacementCumulative incidence of reinterventionValve replacementValve reinterventionCumulative incidenceCoreValve transcatheter aortic valve replacementLow incidence of reinterventionSurgical aortic valve replacement patientsSingle-arm studyFirst-generation CoreValveEvolut R/ProParavalvular regurgitationReinterventionRandomized trialsLow incidenceCoreValvePooled dataTranscatheterIncidenceTreatmentYearsEndocarditis
2023
Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study
Tang G, Spencer J, Rogers T, Grubb K, Gleason P, Gada H, Mahoney P, Dauerman H, Forrest J, Reardon M, Blanke P, Leipsic J, Abdel-Wahab M, Attizzani G, Puri R, Caskey M, Chung C, Chen Y, Dudek D, Allen K, Chhatriwalla A, Htun W, Blackman D, Tarantini G, Sanchez J, Schwartz G, Popma J, Sathananthan J. Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study. Circulation Cardiovascular Interventions 2023, 16: e013238. PMID: 37988439, PMCID: PMC10653288, DOI: 10.1161/circinterventions.123.013238.Peer-Reviewed Original ResearchConceptsRedo-TAVRSAPIEN 3Coronary accessRedo transcatheter aortic valve replacementYounger low-risk patientsFuture coronary accessSAPIEN 3 valveAortic valve replacementLow-risk patientsSelf-expanding valvesPre-TAVR CTValve replacementValve implantationCT planningEvolutImplant positionTomography imagingPatientsCTNodes 4Implant depthTAVRSubstudyNodes 5Valve4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial
Forrest J, Deeb G, Yakubov S, Gada H, Mumtaz M, Ramlawi B, Bajwa T, Teirstein P, Tchétché D, Huang J, Reardon M, Investigators E. 4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. Journal Of The American College Of Cardiology 2023, 82: 2163-2165. PMID: 37877907, DOI: 10.1016/j.jacc.2023.09.813.Peer-Reviewed Original ResearchFeasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy.
Grubb K, Shekiladze N, Spencer J, Perdoncin E, Tang G, Xie J, Lisko J, Sanchez J, Lucas L, Sathananthan J, Rogers T, Deeb G, Fukuhara S, Blanke P, Leipsic J, Forrest J, Reardon M, Gleason P. Feasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy. EuroIntervention 2023, 19: e330-e339. PMID: 37067193, PMCID: PMC10333920, DOI: 10.4244/eij-d-22-01125.Peer-Reviewed Original ResearchConceptsRedo-TAVIFlow compromiseEvolut valvesBalloon-expandable SAPIEN 3Transcatheter aortic valve implantationHigher body mass indexAortic valve implantationAortic root dimensionsBody mass indexSinotubular junction diameterSmaller annulus diameterSAPIEN 3Clinical characteristicsValve implantationTranscatheter valveMass indexAnatomical feasibilityCoronary accessFemale sexCoronary heightsAnnulus diameterHigh riskEvolutLower sinusProcedural variablesTranscatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry
Dallan L, Tang G, Forrest J, Reardon M, Szeto W, Kodali S, Baeza C, Eisenberg R, Attizzani G. Transcatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry. Circulation Cardiovascular Interventions 2023, 16: e012623. PMID: 36943929, PMCID: PMC10022658, DOI: 10.1161/circinterventions.122.012623.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementCardiology Transcatheter Valve Therapy RegistryThoracic Surgeons/American CollegeTranscatheter Valve Therapy RegistryValve replacementAortic stenosisAmerican CollegeMultivariable Cox proportional hazards regression modelsAnnulus sizeCox proportional hazards regression modelProportional hazards regression modelsAortic valve reinterventionTricuspid aortic stenosisReal-world registrySevere aortic stenosisBetter clinical outcomesTreatment of patientsHazards regression modelsComputed tomography angiographyLarge annulusValve reinterventionCause mortalityReadmission ratesValve procedures
2021
Redo‐transcatheter aortic valve replacement with the supra‐annular, self‐expandable Evolut platform: Insights from the Transcatheter valve Therapy Registry
Attizzani GF, Dallan LAP, Forrest JK, Reardon MJ, Szeto WY, Liu F, Pelletier M. Redo‐transcatheter aortic valve replacement with the supra‐annular, self‐expandable Evolut platform: Insights from the Transcatheter valve Therapy Registry. Catheterization And Cardiovascular Interventions 2021, 99: 869-876. PMID: 34533891, DOI: 10.1002/ccd.29941.Peer-Reviewed Original ResearchConceptsTranscatheter Valve Therapy RegistryTranscatheter aortic valveRedo-TAVRTVT RegistryRedo transcatheter aortic valve replacementBetter short-term outcomesTotal aortic regurgitationAortic valve replacementLow-risk patientsShort-term outcomesHospital mortalityIndex hospitalizationAortic regurgitationValve replacementDevice successEvolut RSafety profileMyocardial infarctionAortic valveEvolut PROPatientsRegistryMean gradientOutcomesEvolutA randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesionsOutcomes of Prosthesis-Patient Mismatch Following Supra-Annular Transcatheter Aortic Valve Replacement From the STS/ACC TVT Registry
Tang GHL, Sengupta A, Alexis SL, Bapat VN, Adams DH, Sharma SK, Kini AS, Kodali SK, Ramlawi B, Gada H, Vora AN, Forrest JK, Kaple RK, Liu F, Reardon MJ. Outcomes of Prosthesis-Patient Mismatch Following Supra-Annular Transcatheter Aortic Valve Replacement From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2021, 14: 964-976. PMID: 33958170, DOI: 10.1016/j.jcin.2021.03.040.Peer-Reviewed Original ResearchConceptsSevere prosthesis-patient mismatchTranscatheter aortic valve replacementProsthesis-patient mismatchDe novo stenosisAortic valve replacementTVT RegistryNovo stenosisValve replacementSTS/ACC TVT RegistryHigh residual gradientPre-procedural factorsLong-term outcomesAortic gradientAortic annulusClinical outcomesSurgical bioprosthesesAdverse outcomesClinical impactPatientsResidual gradientReadmissionRegistryMortalityLinear mixed modelsOutcomes
2020
Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study
Wyler von Ballmoos MC, Reardon MJ, Williams MR, Mangi AA, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Oh JK, Qiao H, Forrest JK. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovascular Revascularization Medicine 2020, 26: 12-16. PMID: 33199247, DOI: 10.1016/j.carrev.2020.11.007.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut PRO valveParavalvular regurgitationUS clinical studiesCause mortalityClinical studiesNew York Heart Association class ISelf-expanding transcatheter valveValve Academic Research ConsortiumExtreme surgical riskMild paravalvular regurgitationAcademic Research ConsortiumAortic valve replacementIndependent core laboratoryThree-Year OutcomesSelf-expanding prosthesisLong-term resultsEffective orifice areaValve thrombosisCardiovascular mortalityExcellent hemodynamicsValve replacementEchocardiographic measuresSurgical riskTranscatheter valveImpact of Repositioning on Outcomes Following Transcatheter Aortic Valve Replacement With a Self-Expandable Valve
Attizzani GF, Dallan LAP, Markowitz A, Yakubov SJ, Deeb GM, Reardon MJ, Forrest JK, Mangi AA, Huang J, Popma JJ. Impact of Repositioning on Outcomes Following Transcatheter Aortic Valve Replacement With a Self-Expandable Valve. JACC Cardiovascular Interventions 2020, 13: 1816-1824. PMID: 32763073, DOI: 10.1016/j.jcin.2020.04.028.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisFemaleHeart Valve ProsthesisHumansMaleMultidetector Computed TomographyProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsEvolut RPrimary outcomeValve Academic Research Consortium-2Academic Research Consortium-2Evolut Low Risk trialPrior percutaneous coronary interventionTranscatheter aortic valve replacementEvolut PRO valveLow-risk trialsThoracic Surgeons scoreAortic valve replacementPercutaneous coronary interventionSelf-expandable valvesTranscatheter aortic valveDisabling strokeEvolut valvesSURTAVI trialCause mortalityTrial patientsCoronary interventionSecondary outcomesSurgeons scoreValve replacementClinical outcomesAortic valveThree Generations of Self-Expanding Transcatheter Aortic Valves A Report From the STS/ACC TVT Registry
Forrest JK, Kaple RK, Tang GHL, Yakubov SJ, Nazif TM, Williams MR, Zhang A, Popma JJ, Reardon MJ. Three Generations of Self-Expanding Transcatheter Aortic Valves A Report From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2020, 13: 170-179. PMID: 31973793, DOI: 10.1016/j.jcin.2019.08.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve InsufficiencyAortic Valve StenosisBioprosthesisFemaleHeart Valve ProsthesisHemodynamicsHumansMaleProsthesis DesignRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsEvolut PRO valveTranscatheter aortic valveTVT RegistryAortic regurgitationEvolut RAortic valveSelf-expanding transcatheter aortic valveSTS/ACC TVT RegistryThoracic Surgeons/American CollegeMean aortic valve gradientTranscatheter aortic valve replacement (TAVR) technologyCardiology TVT (Transcatheter Valve Therapy) RegistryTricuspid aortic stenosisAortic valve gradientSignificant aortic regurgitationMild aortic regurgitationSupra-annular valveTranscatheter valve technologyValve gradientHemodynamic statusAortic stenosisAortic annulusEarly outcomesEchocardiographic dataPatient risk
2016
Relationship of Annular Sizing Using Multidetector Computed Tomographic Imaging and Clinical Outcomes After Self-Expanding CoreValve Transcatheter Aortic Valve Replacement
Popma JJ, Gleason TG, Yakubov SJ, Harrison JK, Forrest JK, Maini B, Ruiz CE, Pinto DS, Costa M, Resar J, Conte J, Crestanello J, Chang Y, Oh JK, Reardon MJ, Adams DH. Relationship of Annular Sizing Using Multidetector Computed Tomographic Imaging and Clinical Outcomes After Self-Expanding CoreValve Transcatheter Aortic Valve Replacement. Circulation Cardiovascular Interventions 2016, 9: e003282. PMID: 27369803, DOI: 10.1161/circinterventions.115.003282.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlgorithmsAortic ValveAortic Valve InsufficiencyAortic Valve StenosisClinical Decision-MakingDecision Support TechniquesFemaleGuideline AdherenceHeart Valve ProsthesisHumansMaleMultidetector Computed TomographyPatient SelectionPractice Guidelines as TopicPredictive Value of TestsProsthesis DesignRisk FactorsSeverity of Illness IndexTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsParavalvular aortic regurgitationSevere paravalvular aortic regurgitationSevere aortic stenosisAortic regurgitationValve replacementAortic stenosisClinical outcomesCoreValve transcatheter aortic valve replacementTranscatheter aortic valve replacementSuboptimal surgical candidatesAortic valve replacementClinical end pointsTranscatheter valve replacementTranscatheter heart valve (THV) sizeLower ratesHigher DARPreprocedural multidetectorSurgical candidatesClinical eventsRegurgitationEchocardiographic laboratoryPatientsValve sizeAnnulus perimeterTHV sizing
2015
Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample
Panaich SS, Badheka AO, Arora S, Patel NJ, Thakkar B, Patel N, Singh V, Chothani A, Deshmukh A, Agnihotri K, Jhamnani S, Lahewala S, Manvar S, Panchal V, Patel A, Patel N, Bhatt P, Savani C, Patel J, Savani GT, Solanki S, Patel S, Kaki A, Mohamad T, Elder M, Kondur A, Cleman M, Forrest JK, Schreiber T, Grines C. Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample. Catheterization And Cardiovascular Interventions 2015, 87: 23-33. PMID: 26032938, DOI: 10.1002/ccd.25977.Peer-Reviewed Original ResearchSafety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.
Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015, 11: 75-84. PMID: 25868876, DOI: 10.4244/eijy15m04_01.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlloysAortic ValveAortic Valve StenosisBrain IschemiaBrazilCardiac CatheterizationCognitionCognition DisordersDiffusion Magnetic Resonance ImagingEmbolic Protection DevicesEuropeFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIntracranial EmbolismMalePredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTreatment OutcomeUltrasonography, Doppler, TranscranialConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementNew cerebral ischemic lesionsCerebral diffusion-weighted magnetic resonance imagingCerebral ischemic lesionsDays post procedurePrimary safety endpointDiffusion-weighted magnetic resonance imagingMajor cerebral arteriesTotal lesion volumeMagnetic resonance imagingSafety endpointIschemic lesionsTAVR proceduresCerebral arteryCerebral circulationConsecutive subjectsPost procedureAortic archHistorical controlsLesion volumeResonance imagingDW-MRIPatients
2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV
2012
Transcatheter aortic valve replacement: design, clinical application, and future challenges.
Forrest JK. Transcatheter aortic valve replacement: design, clinical application, and future challenges. The Yale Journal Of Biology And Medicine 2012, 85: 239-47. PMID: 22737052, PMCID: PMC3375667.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementSurgical candidatesAortic stenosisTranscatheter valveSevere symptomatic aortic stenosisSymptomatic aortic stenosisAortic valve replacementEdwards SAPIEN valveQuality of lifeSAPIEN valveMedtronic CoreValveValve replacementClinical resultsPatientsClinical applicationStenosisMechanism of deliveryValveCoreValve